The Challenge recognizes Patient Entrepreneurs with solutions that aid successful, long-term recovery from alcohol and opioid use disorders [01-September-2020] UPPSALA, Sweden and NEW YORK , Sept. 1, 2020 /PRNewswire/ -- Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, an
| UPPSALA, Sweden and NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Orexo AB a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced the 10 Patient Entrepreneurs selected as finalists for the Lyfebulb and Orexo Innovation Challenge in substance use disorders. Motivated by personal connections to addiction and co-morbidities, the following finalists represent companies with unique solutions that address unmet needs afflicting patients and support partners in the recovery journey:
Finalists will pitch their business solutions during the two-day virtual summit on October 14-15, 2020 to an expert panel of judges who represent various facets of the healthcare industry and patient community to assess each solution through a unique lens. The judging panel will include:
The judging panel will select one winner to receive a $25,000 monetary grant to further the development of their business concept. “Our hope with this Innovation Challenge is to become one step closer towards eliminating any and all burdens individuals may face when pursuing, maintaining or supporting a loved one’s recovery.” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “Our timely partnership with Orexo has shed light upon the many unfortunate challenges people still face today, but it also signals the opportunity to respond to those challenges through new innovations. We applaud each entrepreneur’s effort in solving for these unmet needs and look forward to the opportunity of making a lasting impact on the community.” “We are incredibly pleased by the response to the innovation summit initiative and appreciate the engagement manifested the entrepreneurs, who have invested significant time and effort into the program.” said Mikaela Odlander, Director of Digital Therapeutics at Orexo. “We look forward to meeting with the finalists and to continuing our dialogue with this highly diverse set of companies, with a view to support innovative approaches to address the growing issue of substance use disorder.” More information about the challenge may be found on Lyfebulb’s website at https://lyfebulb.com/innovation-award/orexo-2020. About Orexo DTx Orexo DTx is the digital health arm of Orexo AB, a pharmaceutical company that develops and commercializes improved pharmaceuticals and digital therapies. The company addresses unmet needs mainly within the growing space of addiction. Orexo DTx was created in Q4 of 2019 and currently has three products in the pipeline, vorvida® for alcohol misuse, deprexis® for depression, and OXD01 for opioid use disorder, all in partnership with the GAIA group. Orexo DTx’s mission is to redefine treatment of addiction by offering clinically validated digital therapeutics to ensure more successful treatment for patients and cost-effective solutions for payers. The digital products will be commercialized by Orexo DTx worldwide, with the U.S. as the principal market, where Orexo also commercializes its lead product Zubsolv® (buprenorphine and naloxone) sublingual tablets (CIII) for treatment of opioid use disorder. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the U.S. The company is headquartered in Uppsala, Sweden, where research and development activities are performed. For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. About Lyfebulb Lyfebulb is a chronic disease-focused patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, addiction, migraine, transplantation, and chronic cough. See www.lyfebulb.com, Facebook, Twitter, Instagram, Lyfebulb LinkedIn, and Karin Hehenberger LinkedIn. For more information: Orexo Contact: Mikaela Odlander Lyfebulb Contact: Karin Hehenberger, MD, PhD This information was brought to you by Cision http://news.cision.com
SOURCE Orexo | ||
Company Codes: Stockholm:ORX, OTC-PINK:ORXOY, ISIN:SE0000736415, RICS:ORX.ST, Berlin:C5G, LSE:0H19, OTC-PINK:ORXOF, Frankfurt:C5G |
View original content:
